Cargando…

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives

PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotta Ramusino, Matteo, Perini, Giulia, Altomare, Daniele, Barbarino, Paola, Weidner, Wendy, Salvini Porro, Gabriella, Barkhof, Frederik, Rabinovici, Gil D., van der Flier, Wiesje M., Frisoni, Giovanni B., Garibotto, Valentina, Teipel, Stefan, Boccardi, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175294/
https://www.ncbi.nlm.nih.gov/pubmed/33594474
http://dx.doi.org/10.1007/s00259-020-05187-x
_version_ 1783703023951806464
author Cotta Ramusino, Matteo
Perini, Giulia
Altomare, Daniele
Barbarino, Paola
Weidner, Wendy
Salvini Porro, Gabriella
Barkhof, Frederik
Rabinovici, Gil D.
van der Flier, Wiesje M.
Frisoni, Giovanni B.
Garibotto, Valentina
Teipel, Stefan
Boccardi, Marina
author_facet Cotta Ramusino, Matteo
Perini, Giulia
Altomare, Daniele
Barbarino, Paola
Weidner, Wendy
Salvini Porro, Gabriella
Barkhof, Frederik
Rabinovici, Gil D.
van der Flier, Wiesje M.
Frisoni, Giovanni B.
Garibotto, Valentina
Teipel, Stefan
Boccardi, Marina
author_sort Cotta Ramusino, Matteo
collection PubMed
description PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment. RESULTS: Thirty-two studies were eligible. (a) Outcome categories were clinician-centered (found in 25/32 studies, 78%), patient-/caregiver-centered (in 9/32 studies, 28%), and health economics-centered (5/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25/32, 78%) and change in patient management (17/32, 53%); patient-/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8/32, 25%), including quantified burden of procedure for patients’ outcomes (n = 8) (1/8, 12.5%), impact of disclosure of results (6/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5/32, 16%) and impact on quality of life (1/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection. CONCLUSION: Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05187-x.
format Online
Article
Text
id pubmed-8175294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81752942021-06-17 Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives Cotta Ramusino, Matteo Perini, Giulia Altomare, Daniele Barbarino, Paola Weidner, Wendy Salvini Porro, Gabriella Barkhof, Frederik Rabinovici, Gil D. van der Flier, Wiesje M. Frisoni, Giovanni B. Garibotto, Valentina Teipel, Stefan Boccardi, Marina Eur J Nucl Med Mol Imaging Review Article PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment. RESULTS: Thirty-two studies were eligible. (a) Outcome categories were clinician-centered (found in 25/32 studies, 78%), patient-/caregiver-centered (in 9/32 studies, 28%), and health economics-centered (5/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25/32, 78%) and change in patient management (17/32, 53%); patient-/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8/32, 25%), including quantified burden of procedure for patients’ outcomes (n = 8) (1/8, 12.5%), impact of disclosure of results (6/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5/32, 16%) and impact on quality of life (1/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection. CONCLUSION: Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05187-x. Springer Berlin Heidelberg 2021-02-17 2021 /pmc/articles/PMC8175294/ /pubmed/33594474 http://dx.doi.org/10.1007/s00259-020-05187-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Cotta Ramusino, Matteo
Perini, Giulia
Altomare, Daniele
Barbarino, Paola
Weidner, Wendy
Salvini Porro, Gabriella
Barkhof, Frederik
Rabinovici, Gil D.
van der Flier, Wiesje M.
Frisoni, Giovanni B.
Garibotto, Valentina
Teipel, Stefan
Boccardi, Marina
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title_full Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title_fullStr Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title_full_unstemmed Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title_short Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
title_sort outcomes of clinical utility in amyloid-pet studies: state of art and future perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175294/
https://www.ncbi.nlm.nih.gov/pubmed/33594474
http://dx.doi.org/10.1007/s00259-020-05187-x
work_keys_str_mv AT cottaramusinomatteo outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT perinigiulia outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT altomaredaniele outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT barbarinopaola outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT weidnerwendy outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT salviniporrogabriella outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT barkhoffrederik outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT rabinovicigild outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT vanderflierwiesjem outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT frisonigiovannib outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT garibottovalentina outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT teipelstefan outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives
AT boccardimarina outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives